Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Blocking Periostin Prevents Metastasis in a Mouse Cancer Model

By BiotechDaily International staff writers
Posted on 22 Dec 2011
Cancer researchers have identified a protein that seems to be required for cancer cells to metastasize successfully and established secondary tumors at sites distantly removed from the original primary tumor.

Metastatic growth in distant organs is the major cause of cancer mortality, yet this process is inefficient for many cancer types and is accomplished only by a minority of cancer cells that reach distant sites.

Investigators at the Swiss Center for Experimental Cancer Research (Lausanne, Switzerland) worked with a mouse model to look for molecular keys that could enhance a tumor's ability to establish secondary tumors successfully.

They reported in the December 7, 2011, online edition of the journal Nature that a small population of cancer stem cells was critical for metastatic colonization, and that stromal niche signals expressed by potential sites of colonization were crucial to the expansion process. They found that the protein periostin (POSTN), a component of the extracellular matrix, was expressed by fibroblasts in normal tissue and in the stroma of the primary tumor. Infiltrating tumor cells needed to induce stromal POSTN expression in the secondary target organ to initiate colonization. POSTN was required to allow cancer stem cell maintenance, and blocking its function prevented metastasis.

The investigators showed that several conditions were necessary for cancer to propagate. "In particular, we were able to isolate a protein, periostin, in the niches where metastases develop," said senior author Dr. Joerg Huelsken, professor of molecular oncology at the Swiss Center for Experimental Cancer. "Without this protein, the cancer stem cell cannot initiate metastasis; instead, it disappears or remains dormant."

Experimental treatments that blocked periostin activity produced very few side effects in mice, but the investigators caution that this does not necessarily mean the same will hold true in humans.

Related Links:
Swiss Center for Experimental Cancer Research



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.